Keros Therapeutics Share Price (NASDAQ: KROS)

$15.57

▲

0.4

(2.64%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Keros Therapeutics Stock chart to analyse performance

Keros Therapeutics stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$15.21
Today's High:$15.74
$15.57
2.31%
Downside
Day's Volatility :3.37%
Upside
1.08%
52 Weeks Low:$9.12
52 Weeks High:$72.37
$15.57
41.43%
Downside
52 Weeks Volatility :87.4%
Upside
78.49%

Keros Therapeutics Stock Returns

Period	Keros Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	9.13%	6.0%	0.0%
6 Months	45.13%	-6.4%	0.0%
1 Year	-65.51%	-11.1%	0.0%
3 Years	-60.39%	6.7%	-8.6%

Keros Therapeutics Inc Key Stats

Check Keros Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$15.17
Open	$15.39
Today's High	$15.74
Today's Low	$15.21
Market Capitalization	$616.1M
Today's Volume	$675.0K
52 Week High	$72.37
52 Week Low	$9.12
Revenue TTM	$232.8M
EBITDA	$1.7M
Earnings Per Share (EPS)	$0.32
PE Ratio	47.41
Profit Margin	8.06%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	3.33%

Stock Returns calculator for Keros Therapeutics Stock including INR - Dollar returns

The Keros Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Keros Therapeutics investment value today

Current value as on today

₹38,603

Returns

₹61,397

(-61.4%)

Returns from Keros Therapeutics Stock

₹65,712 (-65.71%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Keros Therapeutics Stock

100%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Keros Therapeutics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Keros Therapeutics Inc

Name
Holdings %
Name
Holdings %
Nuveen, LLC
9.72%
BlackRock Inc
6.86%
Vanguard Group Inc
6.48%
JPMorgan Chase & Co
6.40%
Logos Global Management LP
4.92%
Morgan Stanley - Brokerage Accounts
4.18%

Analyst Recommendation on Keros Therapeutics Stock

Rating

Trend

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Keros Therapeutics(by analysts ranked 0 to 5 stars)

Keros Therapeutics Share Price Target

What analysts predicted

Upside of 47.72%

Target:

$23.00

Current:

$15.57

Keros Therapeutics share price target is $23.00, a slight Upside of 47.72% compared to current price of $15.57 as per analysts' prediction.

Keros Therapeutics Stock Insights

Price Movement
In the last 7 days, KROS stock has moved up by 8.1%
KROS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 132.2%
KROS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 105.6% return, outperforming this stock by 165.5%
Price to Sales
ForKROS every $1 of sales, investors are willing to pay $2.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Keros Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$10.0M	↑ 0.0%
Net Income	$-12.3M	↑ 824.64%
Net Profit Margin	-123.44%	↓ 110.09%

	FY20	Y/Y Change
Revenue	$2.5M	↓ 75.0%
Net Income	$-45.4M	↑ 267.47%
Net Profit Margin	-1.8K%	↓ 1691.0%

	FY21	Y/Y Change
Revenue	$20.1M	↑ 704.0%
Net Income	$-58.7M	↑ 29.5%
Net Profit Margin	-292.26%	↑ 1522.18%

	FY22	Y/Y Change
Revenue	$20.0M	↓ 0.5%
Net Income	$-104.7M	↑ 78.2%
Net Profit Margin	-523.4%	↓ 231.14%

	FY23	Y/Y Change
Revenue	$151.0K	↓ 99.24%
Net Income	$-153.0M	↑ 46.15%
Net Profit Margin	-101.3K%	↓ 100795.81%

	FY24	Y/Y Change
Revenue	$3.6M	↑ 2250.99%
Net Income	$-187.4M	↑ 22.46%
Net Profit Margin	-5.3K%	↑ 96041.66%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$83.0K	↓ 41.96%
Net Income	$-43.1M	↑ 7.13%
Net Profit Margin	-51.9K%	↓ 23802.62%

	Q2 FY24	Q/Q Change
Revenue	$37.0K	↓ 55.42%
Net Income	$-45.3M	↑ 4.97%
Net Profit Margin	-122.3K%	↓ 70371.64%

	Q3 FY24	Q/Q Change
Revenue	$388.0K	↑ 948.65%
Net Income	$-53.0M	↑ 17.01%
Net Profit Margin	-13.6K%	↑ 108667.77%

	Q4 FY24	Q/Q Change
Revenue	$3.0M	↑ 684.02%
Net Income	$-46.0M	↓ 13.09%
Net Profit Margin	-1.5K%	↑ 12135.43%

	Q1 FY25	Q/Q Change
Revenue	$211.2M	↑ 6844.31%
Net Income	$148.5M	↓ 422.54%
Net Profit Margin	70.27%	↑ 1583.29%

	Q2 FY25	Q/Q Change
Revenue	$18.2M	↓ 91.4%
Net Income	$-30.7M	↓ 120.68%
Net Profit Margin	-168.96%	↓ 239.23%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-7.3M	↑ 6519.82%

	FY20	Y/Y Change
Profit	$-605.0K	↓ 91.77%

	FY21	Y/Y Change
Profit	$19.2M	↓ 3273.88%

	FY22	Y/Y Change
Profit	$-1.6M	↓ 108.41%

	FY23	Y/Y Change
Profit	$-664.0K	↓ 58.89%

	FY24	Y/Y Change
Profit	$3.6M	↓ 634.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-194.0K	↑ 86.54%

	Q2 FY24	Q/Q Change
Profit	$-269.0K	↑ 38.66%

	Q3 FY24	Q/Q Change
Profit	$74.0K	↓ 127.51%

	Q4 FY24	Q/Q Change
Profit	$2.7M	↑ 3562.16%

	Q1 FY25	Q/Q Change
Profit	$211.2M	↑ 7695.06%

	Q2 FY25	Q/Q Change
Profit	$17.8M	↓ 91.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-16.0M	↓ 327.18%
Investing Cash Flow	$-271.0K	↑ 24.88%
Financing Cash Flow	$14.0K	↓ 99.88%

	FY20	Y/Y Change
Operating Cash Flow	$-36.9M	↑ 130.62%
Investing Cash Flow	$-294.0K	↑ 8.49%
Financing Cash Flow	$296.0M	↑ 2114500.0%

	FY21	Y/Y Change
Operating Cash Flow	$-62.1M	↑ 68.45%
Investing Cash Flow	$-1.0M	↑ 248.3%
Financing Cash Flow	$28.6M	↓ 90.36%

	FY22	Y/Y Change
Operating Cash Flow	$-70.1M	↑ 12.73%
Investing Cash Flow	$-1.2M	↑ 21.19%
Financing Cash Flow	$120.3M	↑ 321.4%

	FY23	Y/Y Change
Operating Cash Flow	$-124.5M	↑ 77.71%
Investing Cash Flow	$-2.5M	↑ 98.55%
Financing Cash Flow	$179.0M	↑ 48.75%

	FY24	Y/Y Change
Operating Cash Flow	$-160.9M	↑ 29.2%
Investing Cash Flow	$-1.9M	↓ 21.63%
Financing Cash Flow	$391.8M	↑ 118.95%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-44.6M	↑ 75.03%
Investing Cash Flow	$-946.0K	↑ 74.86%
Financing Cash Flow	$156.8M	↑ 126.42%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-39.8M	↓ 10.68%
Investing Cash Flow	$-310.0K	↓ 67.23%
Financing Cash Flow	$3.5M	↓ 97.75%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-30.5M	↓ 23.37%
Investing Cash Flow	$-386.0K	↑ 24.52%
Financing Cash Flow	$155.9M	↑ 4316.43%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-46.0M	↑ 50.85%
Investing Cash Flow	$-289.0K	↓ 25.13%
Financing Cash Flow	$75.5M	↓ 51.56%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$161.2M	↓ 450.31%
Investing Cash Flow	$-565.0K	↑ 95.5%
Financing Cash Flow	$4.0K	↓ 99.99%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-29.6M	↓ 118.38%
Investing Cash Flow	$-720.0K	↑ 27.43%
Financing Cash Flow	$17.0K	↑ 325.0%

Keros Therapeutics Technicals Summary

Sell

Neutral

Buy

Keros Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Keros Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Keros Therapeutics Inc	8.3%	45.13%	-65.51%	-60.39%	-69.58%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Keros Therapeutics Inc	47.41	47.41	NA	0.97	0.03	0.0	NA	17.4
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Keros Therapeutics Inc	Buy	$616.1M	-69.58%	47.41	8.06%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

About Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Organization	Keros Therapeutics
Employees	148
CEO	Dr. Jasbir S. Seehra Ph.D.
Industry	Commercial Services

Key Management of Keros Therapeutics Inc

Name	Title
Dr. Jasbir S. Seehra Ph.D.	CEO & Chair of the Board
Mr. Christopher Rovaldi M.Sc.	President & COO
Mr. Keith C. Regnante MBA	Chief Financial Officer
Ms. Esther Cho J.D.	Senior VP, General Counsel & Secretary
Ms. Robin Wagner	Senior Vice President of Human Resources
Mr. John Oram M.B.A.	Senior Vice President of Program & Portfolio Management
Dr. Lorena Lerner Ph.D.	Chief Scientific Officer

Important FAQs about investing in KROS Stock from India :

What is Keros Therapeutics share price today?

Keros Therapeutics share price today is $15.57 as on August 23, 2025 at 1:29 AM IST at the close of the market. Keros Therapeutics share today touched a day high of $15.74 and a low of $15.21.

What is the 52 week high and 52 week low for Keros Therapeutics share?

Keros Therapeutics share touched a 52 week high of $72.37 and a 52 week low of $9.12. Keros Therapeutics stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $15.57, lower by 78.49% versus the 52 week high.

How to invest in Keros Therapeutics Stock (KROS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Keros Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Keros Therapeutics Shares that will get you 0.0963 shares as per Keros Therapeutics share price of $15.57 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Keros Therapeutics Stock (KROS) from India?

Indian investors can start investing in Keros Therapeutics (KROS) shares with as little as ₹87.521 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Keros Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Keros Therapeutics share’s latest price of $15.57 as on August 23, 2025 at 1:29 AM IST, you will get 0.6423 shares of Keros Therapeutics. Learn more about fractional shares .

What are the returns that Keros Therapeutics has given to Indian investors in the last 5 years?

Keros Therapeutics stock has given -69.58% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?